50,000 patients monitored: does finerenone work outside the lab?

NCT ID NCT06278207

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 30 times

Summary

This study looks at 50,000 people in Asia and the US who have chronic kidney disease and type 2 diabetes and are already taking finerenone as part of their regular care. Researchers will collect information from medical records to see how the drug is being used, who is taking it, and how it affects their health. No new treatments or tests are given—this is purely an observation to learn more about real-world outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Bayer
RECRUITING

Berlin, 13353, Germany
Many Locations
COMPLETED

Multiple Locations, New Jersey, 07981, United States
Many Locations
COMPLETED

Multiple Locations, Japan
Many Locations
COMPLETED

Multiple Locations, Taiwan

Conditions

Explore the condition pages connected to this study.

CHRONIC KIDNEY DISEASE TYPE 2 DIABETES MELLITUS